EA200301019A1 - Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин - Google Patents

Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин

Info

Publication number
EA200301019A1
EA200301019A1 EA200301019A EA200301019A EA200301019A1 EA 200301019 A1 EA200301019 A1 EA 200301019A1 EA 200301019 A EA200301019 A EA 200301019A EA 200301019 A EA200301019 A EA 200301019A EA 200301019 A1 EA200301019 A1 EA 200301019A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fatty acid
solvent
pharmaceutical composition
organic amine
cox
Prior art date
Application number
EA200301019A
Other languages
English (en)
Other versions
EA008103B1 (ru
Inventor
Пин Гао
Азиз Карим
Фред Хассан
Джеймс К. Форбс
Original Assignee
Фармасиа Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармасиа Корпорейшн filed Critical Фармасиа Корпорейшн
Publication of EA200301019A1 publication Critical patent/EA200301019A1/ru
Publication of EA008103B1 publication Critical patent/EA008103B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Обеспечивается доставляемая перорально фармацевтическая композиция, содержащая препарат с низкой растворимостью в воде и растворяющую жидкость, которая включает по меньшей мере один фармацевтически приемлемый растворитель, по меньшей мере одну фармацевтически приемлемую жирную кислоту и по меньшей мере один фармацевтически приемлемый органический амин, где (а) существенная часть препарата, например по меньшей мере 15 мас.%, находится в растворенной или солюбилизированной форме в растворяющей жидкости и (б) жирная кислота и органический амин присутствуют в таких общих и относительных количествах, что композиция является тонкодисперсной самоэмульгируемой в симулированной желудочной жидкости.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200301019A 2001-04-17 2002-04-12 Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор сох-2), растворитель, жирную кислоту и органический амин EA008103B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28438101P 2001-04-17 2001-04-17
US32695201P 2001-10-04 2001-10-04
PCT/US2002/011689 WO2002083177A1 (en) 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Publications (2)

Publication Number Publication Date
EA200301019A1 true EA200301019A1 (ru) 2004-06-24
EA008103B1 EA008103B1 (ru) 2007-04-27

Family

ID=26962574

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301019A EA008103B1 (ru) 2001-04-17 2002-04-12 Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор сох-2), растворитель, жирную кислоту и органический амин

Country Status (18)

Country Link
US (1) US20030105141A1 (ru)
EP (1) EP1379279A1 (ru)
JP (1) JP2004530669A (ru)
KR (1) KR20040018355A (ru)
CN (1) CN1516601A (ru)
AR (1) AR033221A1 (ru)
AU (1) AU2002305175B2 (ru)
BR (1) BR0208994A (ru)
CA (1) CA2444220A1 (ru)
CZ (1) CZ20032792A3 (ru)
EA (1) EA008103B1 (ru)
IL (1) IL158201A0 (ru)
MX (1) MXPA03009411A (ru)
NO (1) NO20034629L (ru)
NZ (1) NZ528741A (ru)
PE (1) PE20021145A1 (ru)
PL (1) PL364524A1 (ru)
WO (1) WO2002083177A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1344523A1 (en) * 2002-03-11 2003-09-17 Warner-Lambert Company Ibuprofen solution for hard gelatin capsules
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US20060141470A1 (en) * 2003-02-14 2006-06-29 Kalayoglu Murat V Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
DK2279729T3 (da) * 2003-07-17 2016-11-28 Banner Life Sciences Llc Præparater med kontrolleret frigivelse
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MX2007009888A (es) * 2005-02-17 2007-10-16 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
CN101360485B (zh) * 2005-10-26 2013-04-17 班纳制药公司 作为胶囊填充物的基于亲水性载体的双重控释基质***
JP5406529B2 (ja) 2005-10-26 2014-02-05 バナー ファーマキャプス， インコーポレイテッド カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム
ATE551990T1 (de) * 2007-09-27 2012-04-15 Wockhardt Ltd Selbstemulgierende pharmazeutische zusammensetzungen von rhein oder diacerein
UA102120C2 (ru) * 2008-12-03 2013-06-10 Астеллас Дойчленд Гмбх Пероральная форма дозирования бендамустина
EP2488022B1 (en) 2009-10-16 2018-01-10 Mochida Pharmaceutical Co., Ltd. Compositions
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN103037851A (zh) * 2010-06-02 2013-04-10 安斯泰来德国有限公司 苯达莫司汀的口服剂型
EP2392319A1 (en) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
RU2630617C2 (ru) * 2011-10-18 2017-09-11 Аскат Инк. Фармацевтическая композиция
RU2674982C2 (ru) * 2013-01-14 2018-12-14 ИнФерст Хэлткэр Лимитед Композиции твердых растворов и их применение при сердечно-сосудистом заболевании
MX366317B (es) * 2013-02-04 2019-07-03 Infirst Healthcare Ltd Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
ES2957541T3 (es) 2013-08-27 2024-01-22 Vasilios Voudouris Composiciones farmacéuticas de bendamustina
CN113750043A (zh) * 2021-09-18 2021-12-07 山东省药学科学院 一种塞来昔布自乳化口服液及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL180717B1 (pl) * 1993-11-30 2001-03-30 Searle & Co N o w e 1 -[4-(aminosulfonylo)fenylo]pirazolilobenzenosulfonamidy do leczenia stanów zapalnych PL PL PL PL PL PL PL
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
ZA987800B (en) * 1997-08-27 1999-06-09 Hexal Ag Pharmaceutical composition of meloxicam
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
EP1299122A2 (en) * 2000-07-13 2003-04-09 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain

Also Published As

Publication number Publication date
EA008103B1 (ru) 2007-04-27
AU2002305175B2 (en) 2007-07-12
WO2002083177A1 (en) 2002-10-24
CZ20032792A3 (cs) 2004-04-14
KR20040018355A (ko) 2004-03-03
US20030105141A1 (en) 2003-06-05
NO20034629L (no) 2003-12-10
NO20034629D0 (no) 2003-10-16
JP2004530669A (ja) 2004-10-07
BR0208994A (pt) 2004-04-27
AR033221A1 (es) 2003-12-10
NZ528741A (en) 2005-09-30
CN1516601A (zh) 2004-07-28
PE20021145A1 (es) 2003-01-16
MXPA03009411A (es) 2004-01-29
IL158201A0 (en) 2004-05-12
CA2444220A1 (en) 2002-10-24
EP1379279A1 (en) 2004-01-14
PL364524A1 (en) 2004-12-13

Similar Documents

Publication Publication Date Title
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
EA200300752A1 (ru) Фармацевтическая композиция, имеющая сниженную тенденцию кристаллизации лекарственного ингредиента
BR0309138A (pt) Processo para a preparação de uma composição farmacêutica finamente auto-emulsionável
EA200000703A1 (ru) Сульфонамидные производные в качестве пролекарств, ингибиторов аспартилпротеаз
CY1109135T1 (el) Φαρμακευτικο διαλυμα το οποιο περιλαμβανει ριτοναβιρη, εναν διαλυτη (μακριας αλυσιδας λιπαρο οξυ) και νερο
UY27273A1 (es) Solución oral de arilpiprazol
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
BR0113757A (pt) Derivados de quinolinona como inibibores de tirosina quinase
EA200000702A1 (ru) Пролекарства ингибиторов аспартилпротеаз
KR870002835A (ko) 이온화성 소수성약제의 약제학적 제조방법
UY27320A1 (es) Nuevas composiciones farmacéuticas
NO20025629L (no) Formulering
PT1267832E (pt) Sistema auto-emulsionante de libertacao de farmaco
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
BR0110406A (pt) Formulações lìquidas
ATE505183T1 (de) Den geschmack verdeckende auslaufsichere formulierung
DE60115402D1 (de) Neues selbstemulgierendes arzneistoffverabreichungssystem
NO913295L (no) Kodeinsalt av en substituert karboksylsyre, fremgangsmaatefor fremstilling derav og anvendelse derav.
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
KR927003525A (ko) 술폰아닐리드 유도체 및 의약
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
WO2005041876A3 (en) Spill resistant formulations containing clays
BR9807330A (pt) Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo
BR0011864A (pt) Formulações farmacêuticas
EA200400709A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU